Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review

Pratima Kamada, Arkadiusz Z. Dudek

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are known to have the potential for cardiotoxicity and should be used with caution in patients with cardiac comorbidities. A retrospective review identified two RCC cases treated with sorafenib in the context of preexisting cardiomyopathy. Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted.

Original languageEnglish (US)
Pages (from-to)501-504
Number of pages4
JournalCancer Investigation
Volume28
Issue number5
DOIs
StatePublished - May 1 2010

Keywords

  • Cardiac comorbidities
  • Metastatic renal cell carcinoma
  • Sorafenib tosylate
  • Toxicity

Fingerprint Dive into the research topics of 'Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review'. Together they form a unique fingerprint.

  • Cite this